Adaptive Biotechnologies (Nasdaq: ADPT) boosts MRD 2026 guidance after Q2 revenue hits $71.6M
Rhea-AI Filing Summary
Adaptive Biotechnologies reported second quarter 2026 revenue of $71.6 million, up 22% from a year earlier, led by its Minimal Residual Disease (MRD) segment. MRD revenue reached $66.2 million, a 33% increase, while Immune Medicine revenue was $5.4 million, a 40% decrease, though up 8% excluding prior Genentech-related revenue. clonoSEQ test volume rose 43% to 36,111 tests. Adjusted EBITDA loss narrowed sharply to $0.7 million, compared with a $7.2 million loss in the prior-year quarter.
Net loss was $39.9 million, including a $23.7 million loss on extinguishment of a revenue interest liability tied to settling the OrbiMed Purchase Agreement; excluding this, net loss was $16.2 million. The company completed a $345 million zero-coupon convertible senior notes offering, repaid the OrbiMed obligation, and ended June 30, 2026 with $371.7 million in cash, cash equivalents and marketable securities. Full-year 2026 MRD revenue guidance was raised to $268–$278 million, and total operating expense guidance was set at $350–$355 million. Co-founder and Chief Scientific Officer Harlan Robins will transition to a strategic consultant role focused on MRD R&D and the planned separation of the Immune Medicine business; the company states there are no disagreements or performance issues related to his decision.
Positive
- MRD segment strength and clonoSEQ growth: MRD revenue grew 33% year over year to $66.2 million, and clonoSEQ test volume increased 43% to 36,111 tests, underscoring strong demand for the company’s core diagnostic offering.
- Improved profitability trends: Adjusted EBITDA loss narrowed to just $0.7 million in Q2 2026 from a $7.2 million loss a year earlier, indicating operating leverage despite continued GAAP net losses.
- Enhanced liquidity and capital structure: Completion of a $345 million zero-coupon convertible senior notes offering, repayment of the OrbiMed Purchase Agreement, and $371.7 million in cash, cash equivalents and marketable securities provide substantial financial flexibility.
- Raised MRD revenue guidance: Full-year 2026 MRD revenue guidance increased to $268–$278 million, up from $260–$270 million, implying expected MRD growth of 26%–31% and signaling management’s confidence in the segment.
Negative
- Continued and higher GAAP net losses: Q2 2026 net loss was $39.9 million versus $25.6 million a year earlier, driven in part by a $23.7 million loss on revenue interest liability extinguishment and ongoing losses in the Immune Medicine segment.
Filing Explained
As of June 30, 2026, 159,059,622 common shares were outstanding, while Robins’s expected consulting agreement had not yet been entered.
The filing states that Harlan Robins decided on
At
The supplied dilution definition explains that issuing additional shares increases the total share count and reduces an existing holder’s percentage ownership absent offsetting changes. This filing reports the two share counts but does not identify the cause of their difference.
The specified resolution point is whether the company enters the expected consulting agreement and what support terms it provides for MRD research and development and the Immune Medicine separation.
8-K Event Classification
Key Figures
Key Terms
Minimal Residual Disease medical
clonoSEQ medical
zero-coupon convertible senior notes financial
Adjusted EBITDA financial
revenue interest liability extinguishment financial
Offering Details
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Adaptive Biotechnologies (ADPT) perform financially in Q2 2026?
How strong was the MRD business for ADPT in the quarter ended June 30, 2026?
What guidance did Adaptive Biotechnologies (ADPT) provide for 2026?
How did the Immune Medicine segment of ADPT perform in Q2 2026?
What is Adaptive Biotechnologies’ (ADPT) liquidity and debt position after Q2 2026?
What leadership change did Adaptive Biotechnologies (ADPT) announce?
How did Adjusted EBITDA trend for Adaptive Biotechnologies (ADPT) in Q2 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 |
Results of Operations and Financial Condition. |
On July 29, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On July 24, 2026, the Company’s Chief Scientific Officer and Co-founder, Dr. Harlan Robins, decided to transition into a strategic consultant role with the Company. The Company expects to enter into a consulting agreement with Dr. Robins on its standard form pursuant to which he would support research and development efforts for the minimal residual disease business and the separation of the immune medicine business. There are no disagreements or performance matters related to Dr. Robins's decision.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit Number |
|
Description |
99.1 |
|
Press Release dated July 29, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Adaptive Biotechnologies Corporation |
|
|
|
|
|
Date: July 29, 2026 |
|
By: |
/s/ Kyle Piskel |
|
|
|
Kyle Piskel |
|
|
|
Chief Financial Officer |
EXHIBIT 99.1
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026.
“We delivered an exceptional second quarter, driven by expanding growth and profitability in MRD, including both our clinical and biopharma businesses,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “The combination of our operating performance, fortified balance sheet and plan to separate the Immune Medicine business enhances our ability to create long-term value for our shareholders.”
Recent Highlights
Second Quarter 2026 Financial Results
Revenue was $71.6 million for the quarter ended June 30, 2026, representing a 22% increase from the second quarter in the prior year. Excluding revenue recognized under the Genentech Agreement, which did not generate revenue in the quarter ended June 30, 2026, revenue for the current quarter increased 30% from the second quarter in the prior year. MRD revenue was $66.2 million for the quarter, representing a 33% increase from the second quarter in the prior year. Immune Medicine revenue was $5.4 million for the quarter, representing a 40% decrease from the second quarter in the prior year. Excluding revenue generated from the Genentech Agreement, Immune Medicine revenue for the quarter ended June 30, 2026 increased 8% from the second quarter in the prior year.
Operating expenses for the second quarter of 2026 were $87.3 million, compared to $83.9 million in the second quarter of the prior year, representing an increase of 4%.
Interest and other income, net was $2.3 million for the second quarter of 2026, compared to $2.4 million in the second quarter of the prior year. Interest expense was $2.7 million for the second quarter of 2026, compared to $2.9 million in the second quarter of the prior year.
Net loss was $39.9 million for the second quarter of 2026, compared to $25.6 million for the same period in 2025. Excluding the loss recognized on the settlement of the OrbiMed Purchase Agreement, net loss was $16.2 million for the second quarter of 2026. Excluding revenue generated from the Genentech Agreement, net loss was $29.5 million for the second quarter of 2025.
Adjusted EBITDA (non-GAAP) was a loss of $0.7 million for the second quarter of 2026, compared to a loss of $7.2 million for the second quarter of the prior year. Excluding revenue generated from the Genentech Agreement, Adjusted EBITDA was a loss of $11.1 million for the second quarter of 2025.
Cash, cash equivalents and marketable securities was $371.7 million as of June 30, 2026, inclusive of $15.1 million of cash and cash equivalents held by Digital Biotechnologies, Inc.
2026 Updated Financial Guidance
Adaptive Biotechnologies expects full year revenue for the MRD business to be between $268 million and $278 million, updated from the previous range between $260 million and $270 million. No revenue guidance is provided for the Immune Medicine business.
We expect full year total company operating expenses, including cost of revenue, to be between $350 million and $355 million, updated from the previous range between $350 million and $360 million.
Management will provide further details on the outlook during the conference call.
Webcast and Conference Call Information
Adaptive Biotechnologies will host a conference call to discuss its second quarter 2026 financial results after market close on Wednesday, July 29, 2026 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Use of Non-GAAP Financial Measure
To supplement our unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, impairment costs for long-lived assets, restructuring expense, share-based compensation expense and revenue interest liability extinguishment loss. We define our segment Adjusted EBITDA in the same way to the extent the net loss attributable to Adaptive Biotechnologies Corporation and adjustments are allocable to each segment. We have provided reconciliations of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.
Management uses Adjusted EBITDA, including segment Adjusted EBITDA, to evaluate the financial performance of our business and segments and to evaluate the effectiveness of our strategies. We present these figures because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.
Adjusted EBITDA, including segment Adjusted EBITDA, has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments we make. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA, including segment Adjusted EBITDA, does not reflect:
In addition, Adjusted EBITDA, including segment Adjusted EBITDA, may not be comparable to similarly titled measures used by other companies in our industry or across different industries.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
Adaptive Biotechnologies
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Revenue |
|
$ |
71,553 |
|
|
$ |
58,879 |
|
|
$ |
142,427 |
|
|
$ |
111,322 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of revenue |
|
|
20,165 |
|
|
|
17,999 |
|
|
|
38,873 |
|
|
|
34,978 |
|
Research and development |
|
|
19,153 |
|
|
|
24,134 |
|
|
|
42,776 |
|
|
|
48,337 |
|
Sales and marketing |
|
|
26,414 |
|
|
|
23,573 |
|
|
|
52,760 |
|
|
|
46,620 |
|
General and administrative |
|
|
21,168 |
|
|
|
17,786 |
|
|
|
42,152 |
|
|
|
35,185 |
|
Amortization of intangible assets |
|
|
423 |
|
|
|
423 |
|
|
|
842 |
|
|
|
842 |
|
Total operating expenses |
|
|
87,323 |
|
|
|
83,915 |
|
|
|
177,403 |
|
|
|
165,962 |
|
Loss from operations |
|
|
(15,770 |
) |
|
|
(25,036 |
) |
|
|
(34,976 |
) |
|
|
(54,640 |
) |
Interest and other income, net |
|
|
2,256 |
|
|
|
2,391 |
|
|
|
4,336 |
|
|
|
5,070 |
|
Interest expense |
|
|
(2,694 |
) |
|
|
(2,948 |
) |
|
|
(5,583 |
) |
|
|
(5,853 |
) |
Loss on revenue interest liability extinguishment |
|
|
(23,733 |
) |
|
|
— |
|
|
|
(23,733 |
) |
|
|
— |
|
Net loss |
|
|
(39,941 |
) |
|
|
(25,593 |
) |
|
|
(59,956 |
) |
|
|
(55,423 |
) |
Add: Net loss (income) attributable to noncontrolling interest |
|
|
153 |
|
|
|
(21 |
) |
|
|
135 |
|
|
|
(43 |
) |
Net loss attributable to Adaptive Biotechnologies Corporation |
|
$ |
(39,788 |
) |
|
$ |
(25,614 |
) |
|
$ |
(59,821 |
) |
|
$ |
(55,466 |
) |
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |
|
$ |
(0.25 |
) |
|
$ |
(0.17 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.37 |
) |
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |
|
|
159,855,257 |
|
|
|
152,082,284 |
|
|
|
157,700,126 |
|
|
|
150,646,632 |
|
Adaptive Biotechnologies
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
||
|
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
169,873 |
|
|
$ |
70,495 |
|
Short-term marketable securities (amortized cost of $174,510 and $156,246, respectively) |
|
|
174,382 |
|
|
|
156,485 |
|
Accounts receivable, net |
|
|
49,513 |
|
|
|
50,365 |
|
Inventory |
|
|
10,497 |
|
|
|
9,820 |
|
Prepaid expenses and other current assets |
|
|
16,298 |
|
|
|
13,020 |
|
Total current assets |
|
|
420,563 |
|
|
|
300,185 |
|
Long-term assets |
|
|
|
|
|
|
||
Property and equipment, net |
|
|
29,451 |
|
|
|
34,107 |
|
Operating lease right-of-use assets |
|
|
39,122 |
|
|
|
40,616 |
|
Long-term marketable securities (amortized cost of $27,564 and $13,220, respectively) |
|
|
27,480 |
|
|
|
13,234 |
|
Restricted cash |
|
|
2,728 |
|
|
|
2,689 |
|
Intangible assets, net |
|
|
884 |
|
|
|
1,726 |
|
Goodwill |
|
|
118,972 |
|
|
|
118,972 |
|
Other assets |
|
|
1,478 |
|
|
|
1,207 |
|
Total assets |
|
$ |
640,678 |
|
|
$ |
512,736 |
|
Liabilities and shareholders’ equity |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
5,241 |
|
|
$ |
6,467 |
|
Accrued liabilities |
|
|
10,651 |
|
|
|
7,700 |
|
Accrued compensation and benefits |
|
|
9,742 |
|
|
|
16,992 |
|
Current portion of operating lease liabilities |
|
|
8,823 |
|
|
|
8,920 |
|
Current portion of deferred revenue |
|
|
53,255 |
|
|
|
45,194 |
|
Current portion of revenue interest liability, net |
|
|
— |
|
|
|
4,642 |
|
Total current liabilities |
|
|
87,712 |
|
|
|
89,915 |
|
Long-term liabilities |
|
|
|
|
|
|
||
Operating lease liabilities, less current portion |
|
|
66,800 |
|
|
|
70,228 |
|
Deferred revenue, less current portion |
|
|
608 |
|
|
|
1,006 |
|
Revenue interest liability, net, less current portion |
|
|
— |
|
|
|
126,566 |
|
Convertible senior notes, net |
|
|
334,876 |
|
|
|
— |
|
Other long-term liabilities |
|
|
20 |
|
|
|
20 |
|
Total liabilities |
|
|
490,016 |
|
|
|
287,735 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Shareholders’ equity |
|
|
|
|
|
|
||
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025 |
|
|
— |
|
|
|
— |
|
Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2026 and December 31, 2025; 159,059,622 and 153,779,418 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively |
|
|
16 |
|
|
|
15 |
|
Additional paid-in capital |
|
|
1,566,254 |
|
|
|
1,581,848 |
|
Accumulated other comprehensive (loss) gain |
|
|
(212 |
) |
|
|
253 |
|
Accumulated deficit |
|
|
(1,423,144 |
) |
|
|
(1,363,323 |
) |
Total Adaptive Biotechnologies Corporation shareholders’ equity |
|
|
142,914 |
|
|
|
218,793 |
|
Noncontrolling interest |
|
|
7,748 |
|
|
|
6,208 |
|
Total shareholders’ equity |
|
|
150,662 |
|
|
|
225,001 |
|
Total liabilities and shareholders’ equity |
|
$ |
640,678 |
|
|
$ |
512,736 |
|
Adjusted EBITDA
The following is a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA for the periods presented (in thousands, unaudited):
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Net loss attributable to Adaptive Biotechnologies Corporation |
|
$ |
(39,788 |
) |
|
$ |
(25,614 |
) |
|
$ |
(59,821 |
) |
|
$ |
(55,466 |
) |
Interest and other income, net |
|
|
(2,256 |
) |
|
|
(2,391 |
) |
|
|
(4,336 |
) |
|
|
(5,070 |
) |
Interest expense |
|
|
2,694 |
|
|
|
2,948 |
|
|
|
5,583 |
|
|
|
5,853 |
|
Depreciation and amortization expense |
|
|
3,695 |
|
|
|
4,502 |
|
|
|
7,532 |
|
|
|
9,233 |
|
Impairment of long-lived assets |
|
|
— |
|
|
|
— |
|
|
|
347 |
|
|
|
— |
|
Restructuring expense |
|
|
77 |
|
|
|
— |
|
|
|
720 |
|
|
|
— |
|
Share-based compensation expense |
|
|
11,119 |
|
|
|
13,359 |
|
|
|
23,047 |
|
|
|
25,506 |
|
Loss on revenue interest liability extinguishment |
|
|
23,733 |
|
|
|
— |
|
|
|
23,733 |
|
|
|
— |
|
Adjusted EBITDA |
|
$ |
(726 |
) |
|
$ |
(7,196 |
) |
|
$ |
(3,195 |
) |
|
$ |
(19,944 |
) |
Segment Information (Including Segment Adjusted EBITDA)
The following sets forth segment information for the periods presented (in thousands, unaudited):
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
MRD: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Revenue |
|
$ |
66,168 |
|
|
$ |
49,938 |
|
|
$ |
133,261 |
|
|
$ |
93,659 |
|
Adjusted EBITDA |
|
|
9,116 |
|
|
|
1,912 |
|
|
|
21,254 |
|
|
|
(2,199 |
) |
Reconciliation of Net Income (Loss) to Adjusted EBITDA: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income (loss) |
|
$ |
382 |
|
|
$ |
(7,180 |
) |
|
$ |
3,744 |
|
|
$ |
(19,418 |
) |
Depreciation and amortization expense |
|
|
2,409 |
|
|
|
2,455 |
|
|
|
4,790 |
|
|
|
5,118 |
|
Impairment of long-lived assets |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Restructuring expense |
|
|
77 |
|
|
|
— |
|
|
|
325 |
|
|
|
— |
|
Share-based compensation expense |
|
|
6,248 |
|
|
|
6,637 |
|
|
|
12,395 |
|
|
|
12,101 |
|
Adjusted EBITDA |
|
$ |
9,116 |
|
|
$ |
1,912 |
|
|
$ |
21,254 |
|
|
$ |
(2,199 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Immune Medicine(1): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Revenue |
|
$ |
5,385 |
|
|
$ |
8,941 |
|
|
$ |
9,166 |
|
|
$ |
17,663 |
|
Adjusted EBITDA |
|
|
(6,269 |
) |
|
|
(5,721 |
) |
|
|
(16,629 |
) |
|
|
(10,827 |
) |
Reconciliation of Net Loss to Adjusted EBITDA: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
$ |
(10,055 |
) |
|
$ |
(11,770 |
) |
|
$ |
(25,984 |
) |
|
$ |
(22,689 |
) |
Depreciation and amortization expense |
|
|
826 |
|
|
|
1,585 |
|
|
|
1,831 |
|
|
|
3,208 |
|
Impairment of long-lived assets |
|
|
— |
|
|
|
— |
|
|
|
347 |
|
|
|
— |
|
Restructuring expense |
|
|
— |
|
|
|
— |
|
|
|
395 |
|
|
|
— |
|
Share-based compensation expense |
|
|
2,960 |
|
|
|
4,464 |
|
|
|
6,782 |
|
|
|
8,654 |
|
Adjusted EBITDA |
|
$ |
(6,269 |
) |
|
$ |
(5,721 |
) |
|
$ |
(16,629 |
) |
|
$ |
(10,827 |
) |
(1) Expenses related to Digital Biotechnologies, Inc. are no longer included in the Immune Medicine segment.